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ABSTRACT
Previous reports showed that raltegravir, a recently approved antiviral compound that targets HIV integrase, can inhibit the nu-
clease function of human cytomegalovirus (HCMV terminase) in vitro. In this study, subtoxic levels of raltegravir were shown to
inhibit the replication of four different herpesviruses, herpes simplex virus 1 (HSV-1), HSV-2, HCMV, and mouse cytomegalovi-
rus, by 30- to 700-fold, depending on the dose and the virus tested. Southern blotting and quantitative PCR revealed that ralte-
gravir inhibits DNA replication of HSV-1 rather than cleavage of viral DNA. A raltegravir-resistant HSV-1 mutant was generated
by repeated passage in the presence of 200 M raltegravir. The genomic sequence of the resistant virus, designated clone 7, con-
tained mutations in 16 open reading frames. Of these, the mutations F198S in unique long region 15 (UL15; encoding the large
terminase subunit), A374V in UL32 (required for DNA cleavage and packaging), V296I in UL42 (encoding the DNA polymerase
accessory factor), and A224S in UL54 (encoding ICP27, an important transcriptional regulator) were introduced independently
into the wild-type HSV-1(F) genome, and the recombinant viruses were tested for raltegravir resistance. Viruses bearing both
the UL15 and UL32 mutations inserted within the genome of the UL42 mutant were also tested. While the UL15, UL32, and UL54
mutant viruses were fully susceptible to raltegravir, any virus bearing the UL42 mutation was as resistant to raltegravir as clone
7. Overall, these results suggest that raltegravir may be a valuable therapeutic agent against herpesviruses and the antiviral activ-
ity targets the DNA polymerase accessory factor rather than the nuclease activity of the terminase.
IMPORTANCE
This paper shows that raltegravir, the antiretrovirus drug targeting integrase, is effective against various herpesviruses. Drug
resistance mapped to the herpesvirus DNA polymerase accessory factor, which was an unexpected finding.
Herpesviruses cause a number of important diseases in animalsand humans, including recurrent skin lesions, blindness,
birth defects, transplant rejection, encephalitis, and cancers of the
skin and lymphoid tissue. Moreover, herpesvirus infection com-
monly worsens the clinical course of human immunodeficiency
virus (HIV) infection, and HIV type 1 (HIV-1) has frequently
been recovered from genital herpes lesions in coinfected individ-
uals (1).
All herpesviruses encode a highly conserved terminase com-
prising three subunits (1–3). The terminase cleaves concatameric
DNA that has accumulated within the nuclei of infected cells into
unit-length genomes, docks with the portal vertex of the capsid,
and pumps the DNA into the capsid through the hydrolysis of
ATP (4, 5). Given its high conservation and importance to repli-
cation, the terminase represents an important antiviral drug target
(2, 6). The three-dimensional structures of the nuclease domains
of terminase subunits encoded by unique long region 89 (UL89) of
human cytomegalovirus (HCMV; or human herpesvirus 5) and
UL15 of herpes simplex virus 1 (HSV-1) are highly similar and
reveal an RNase H/integrase-like fold (7, 8).
Raltegravir (MK-0518; Isentress; Merck & Co. Inc., White-
house Station, NJ) is a member of a novel class of antiretroviral
drugs that blocks the integration of HIV-1 cDNA into the cellular
genome (9, 10). This compound binds an active site within an
RNase H-like fold of integrase to prevent the initiation of strand
transfer (11–13). Importantly for the hypotheses initiating this
study, the nuclease activity of the UL89 protein (pUL89) could be
inactivated by raltegravir in vitro (8). As a follow-up to these ob-
servations, the current studies were undertaken to determine
whether raltegravir could inhibit herpesvirus replication, with the
expectation that raltegravir would inhibit HSV and HCMV repli-
cation by blocking the nuclease activity of the terminase. Although
we did note substantial antiviral activity against herpesviruses, we
were surprised to find that raltegravir inhibited DNA replication
rather than terminase-mediated viral DNA cleavage and packag-
ing. Moreover, drug resistance to raltegravir mapped to the DNA
polymerase accessory factor encoded by HSV-1 UL42. These data
suggest a novel therapeutic avenue against dual HIV and herpes-
virus infections but suggest that long-term raltegravir treatment
may favor the emergence of drug-resistant viruses.
MATERIALS AND METHODS
Cells, viruses, and plasmids. The cell lines CV1 and FS-2 were purchased
from ATCC, and cells of these lines were propagated in Dulbecco’s mod-
ified Eagle medium (DMEM) supplemented with 10% newborn calf se-
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rum, 100 U/ml of penicillin, and 100 g/ml streptomycin. The cell line
M210B4 was purchased from ATCC, and M210B4 cells were propagated
in RPMI 1640 medium supplemented with 10% newborn calf serum, 100
U/ml of penicillin, and 100 g/ml streptomycin. To minimize genetic
changes, all viral stocks were maintained as mother pools that were used to
seed working stocks. The herpes simplex virus 1 F strain [HSV-1(F)],
referred to as the wild type in this study, was from Bernard Roizman (14).
Herpes simplex virus 2 strain G was also a gift from Bernard Roizman
(14). The mouse cytomegalovirus (MCMV) Smith strain was a gift from
Brian D. Rudd (Department of Microbiology and Immunology, Cornell
University), and the HCMV Towne strain was a gift from Greg Pari, Uni-
versity of Nevada, Reno, School of Medicine. The HSV-1(F) bacterial
artificial chromosome (BAC) was obtained from Y. Kawaguchi, Univer-
sity of Tokyo (15), and plasmid pEP-kan-S, used in BAC mutagenesis, was
obtained from Klaus Osterrieder, University of Berlin. The GS1783 bac-
terial Escherichia coli host strain was obtained from Greg Smith, North-
western University. Plasmid pCAGGS-nlsCre, expressing Cre recombi-
nase, was from Michael Kotlikoff, Cornell University.
Toxicity testing. Raltegravir cytotoxicity was determined by a cell pro-
liferation assay according to the manufacturer’s protocol (CellTiter 96
AQueous One Solution cell proliferation assay; Promega). Briefly, cells of
the CV1, FS-2, and M210B4 cell lines were grown in 24-well plates. At 80%
confluence, medium only or medium containing either dimethyl sulfox-
ide (DMSO) or raltegravir at various concentrations was added. After
incubation for 24 h at 37°C, 40 l of the manufacturer’s reagent was added
to the cells. The plates were then incubated for 2 h at 37°C, and the absor-
bance at 490 nm was read with a plate reader (ELX800; Bio-Tex).
Raltegravir treatment. Four separate experiments were performed to
test for the antiherpesvirus activity of raltegravir. First, 1.2  106 CV1 cells
were seeded into 6-well plates and infected with HSV-1(F) or HSV-2 at a
multiplicity of infection (MOI) of 0.01. After virus adsorption and wash-
ing, the cells were maintained in medium containing raltegravir at various
concentrations (10, 100, 200, or 400 M) or an equivalent volume of the
DMSO carrier. At 24 h postinfection (hpi), the virus within the cells was
harvested by three cycles of freezing and thawing, and standard plaque
assays were performed on CV1 cells to quantify viral infectivity. Second,
1.2  106 FS-2 cells were seeded into 6-well plates and infected with
HCMV at an MOI of 0.01. After virus adsorption and washing, raltegravir
at various concentrations (10, 100, 200, or 400 M) or an equivalent
volume of DMSO was added. Drug or carrier levels were maintained by
replacing the medium every 24 h. At 72 hpi, the virus within the cells was
harvested by freezing and thawing three times, and to quantify infectivity
a plaque assay was performed as described above but with some modifi-
cations. In brief, 1.2  106 FS-2 cells were seeded into 6-well plates, in-
fected with 10-fold serially diluted HCMV, and then treated with various
concentrations of raltegravir. At 5 days postinfection (dpi), the plaques
were counted to quantify the viral infectivity. Third, 1.2  106 M210B4
cells were seeded into each well of 6-well plates and infected with MCMV
at an MOI of 0.01. After virus adsorption and washing, the cells were
maintained in medium containing various concentrations (10, 100, 200,
or 400 M) of raltegravir or the amount of DMSO that served as the
carrier. Medium was replaced every 24 h with fresh medium containing
similar levels of drug or carrier. At 72 hpi, the virus within the cells was
harvested by freezing-thawing three times, and the amount of infectivity
was quantified by plaque assay on M210B4 cells as described above but
with some modifications. In brief, 1.2  106 M210B4 cells were seeded
into 6-well plates and infected with 10-fold serially diluted MCMV from
cells treated with various concentrations of raltegravir, as indicated in
Results. At 5 dpi, the viral infectivity was determined by plaque assay on
fresh monolayers of the same cells.
Southern blot assays. Three 60-mm plates of CV1 cells were infected
with HSV-1(F) at an MOI of 5. After virus adsorption and washing, in-
fected cells were maintained in the presence of 200 M raltegravir or the
DMSO carrier. Uninfected cells served as an additional control. At 18 hpi,
the medium was removed and the cells were washed in phosphate-buff-
ered saline (PBS), removed by scraping, and pelleted by centrifugation at
1,000  g for 5 min. The cells were lysed, and total cellular DNA was
extracted as described previously (16). Briefly, nuclei were lysed in SDS,
followed by treatment with proteinase K and phenol-chloroform extrac-
tion. Approximately 10 g of total DNA was digested with BamHI and
electrophoretically separated on 0.8% agarose gels. The DNA fragments
were denatured, neutralized, and transferred to a nylon membrane as
described previously (17). The bound DNA was UV cross-linked to the
nylon membranes and hybridized with the [32P]dCTP-labeled BamHI P
fragment of HSV-1(F) DNA. The bound probe was visualized by exposure
to X-ray film at 80°C in the presence of an intensifying screen.
qPCR. Viral genome replication was measured by real-time quantita-
tive PCR (qPCR) as described with some modifications (18). Target prim-
ers for UL42 and reference primers for 18S rRNA (listed in Table 1) were
used to measure DNA replication. qPCR was carried out with SYBR green
(Thermo Scientific, Pittsburgh, PA) according to the manufacturer’s di-
rections. Briefly, amplification reactions were performed in a volume of
25 l with 5 pmol of each primer, 100 ng DNA, and 12.5 l 2  SYBR
green mix. The thermal cycling conditions included an initial denatur-
ation for 10 min at 95°C and 40 cycles consisting of a denaturation step at
95°C for 15 s, an annealing step at 60°C for 30 s, and an extension step for
30 s at 72°C. Each sample was analyzed in triplicate, and average threshold
cycle (CT) values were used for further analysis. Relative amounts of DNA
were determined by the 2CT method, which uses the difference of the
CT value of the target gene subtracted from the value of 18S rRNA in the
raltegravir-treated sample minus this value in the DMSO-treated sample
(18).
Generation of drug-resistant virus. HSV-1-infected CV1 cells were
maintained in medium containing 200 M raltegravir. Fresh medium
containing the drug of the same concentration was exchanged every 24 h,
and progeny virus was harvested after a cytopathic effect (CPE) was evi-
dent. These F1 progeny were passaged under the same conditions, and F2
progeny were harvested after the onset of a CPE. This process of infection
and collection of progeny in the presence of raltegravir was repeated a
total of 10 times. The F10 progeny viruses were plaque purified, grown to
a high titer, and tested for raltegravir resistance by plaque assay. Viruses
were plaque purified in the presence of raltegravir, and a virus with a high
level of resistance was designated clone 7. This virus was passaged five
more times in the presence of 200 M raltegravir, after which its genome
was sequenced. The level of drug resistance was then determined by
plaque assay in the presence and absence of 200 M raltegravir.
Pure genomic DNA preparation. Genomic DNA was extracted from
capsids purified from cells infected with the clone 7 mutant as described
previously (19). Viral DNA was purified by phenol-chloroform extraction
and ethanol precipitation, resuspended in deionized water, and stored at
20°C.
Genome sequencing and alignment of mutant virus. Genome se-
quencing was performed by the Cornell University DNA Sequencing and
Genotyping Core Facility. Illumina libraries were constructed using 1-g
purified DNA samples according to the manufacturer’s protocol. Librar-
ies were sequenced using single-end cluster generation kits and 100-cycle
sequencing kits (Illumina) on an Illumina HiSeq2000 sequencing system
following the manufacturer’s instructions. Base calling and initial data
processing were performed using the standard Illumina pipeline. Reads
that passed Illumina quality control were aligned to the HSV-1(F) refer-
ence genome sequence (GenBank accession number GU734771) using
TABLE 1 Primers used for qPCR
Primer name Primer sequence (orientation 5=¡ 3=)
18S forward CCA GTA AGT GCG GGT CAT AAG C
18S reverse GCC TCA CTA AAC CAT CCA ATC GG
UL42 forward GCG GTA TCG GCG GTA TTT
UL42 reverse CCC GTC TTA GGT TTC TTT AGG G
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the Burrows-Wheeler aligner (BWA). Unique mapping reads with no
more than 2 mismatches were used for single nucleotide polymorphism
(SNP) calling. SNPs were called by use of the SAMtools Mpileup com-
mand with default options (20, 21).
Virus growth kinetics analysis. CV1 cells were infected with HSV-
1(F) or clone 7 at an MOI of 0.01. At different time points, cell cultures
were collected, cell-associated virus was released by 3 freeze-thaw cycles,
and virus titers were determined by plaque assay.
Genetic rescue and generation of recombinant viruses. Mutations in
UL15 (F198S), UL32 (A374V), UL42 (V296I), and UL54 (A224S) matching
the changes in clone 7 viral DNA were introduced into the HSV-1(F) viral
genome by en passant mutagenesis (22). Infectious virus was generated by
transfection of BAC DNA into CV1 cells as described previously (15, 23).
The primers used were as follows (underlining indicates the mutated
codon): 5= GGG CGG TAC CGC GAC GAT TAT ATC ATC TTT GCC
CTG GAG CAC TCT TTT CTC CGC GCG CTC ACG GGC TAG GGA
TAA CAG GGT AAT CGA TTT 3= (forward) and 5=GGC GAT GTC GGC
GGG GGC CGA GCC CGT GAG CGC GCG GAG AAA AGA GTG CTC
CAG GGC AAA GAT GAT GCC AGT GTT ACA ACC AAT TAA CC 3=
(reverse) for the UL15 mutation, 5=CGC AAA GCG CGG AGC CAC GTC
GCG CGT GCG TGC CCC GCG ATG CAC TTC CCA GGA CTG GCG
GAC CGT TAG GGA TAA CAG GGT AAT CGA TTT 3= (forward) and 5=
GCC GCG GAG GCC CGT CGC GCC ACG GTC CGC CAG TCC TGG
GAA GTG CAT CGC GGG GCA CGC ACG CGC GCC AGT GTT ACA
ACC AAT TAA CC 3= (reverse) for the UL32 mutation, 5=CAG GTC GCC
GGG GGC ACC CTC AAG TTC TTC CTC ACG ACC CCC ATC CCC
AGT CTG TGC GTC ACC GCC TAG GGA TAA CAG GGT AAT CGA
TTT 3= (forward) and 5=CGA TAC CGC GTT GGG ACC GGT GGC GGT
GAC GCA CAG ACT GGG GAT GGG GGT CGT GAG GAA GAA CTT
GCC AGT GTT ACA ACC AAT TAA CC 3= (reverse) for the UL42 muta-
tion, and 5= GGC GTG CGC CAA GCA CCC CCC CCG CTA ATG ACG
CTG GCG ATT TCC CCC CCG CCC GCG GAC CCC CGC TAG GGA
TAA CAG GGT AAT CGA TTT 3= (forward) and 5=CTT TCG CTC CGG
GGC CGG GGC GCG GGG GTC CGC GGG CGG GGG GGA AAT CGC
CAG CGT CAT TAG CGG GCC AGT GTT ACA ACC AAT TAA CC 3=
(reverse) for the UL54 mutation. Viruses with double mutations in UL15/
UL42 and UL32/UL42 were derived by using the primers for UL15 and
UL32 to insert the respective mutations into UL42 mutant BAC DNA.
The resulting BAC DNAs were cotransfected separately into CV1 cells
with a Cre recombinase expression plasmid, and the reconstituted viruses
were plaque purified. The genotypes of the mutant viruses were confirmed
by restriction fragment length polymorphism analysis and DNA sequenc-
ing of PCR amplicons of the relevant regions (data not shown).
Statistical analysis. Student’s t test was used to compare the amounts
of DNA purified from pairs of treated or untreated groups of cells. All
statistical analyses and calculations were done using GraphPad Prism
(version 5) software (GraphPad Software Inc., La Jolla, CA).
Nucleotide sequence accession numbers. The sequences determined
in this study have been deposited in GenBank under accession numbers
KM259925 to KM259928.
RESULTS
To ensure that experiments were conducted using nontoxic doses
of raltegravir, the cell lines CV1, FS-2, and M210B4 were treated
with 0 to 1,600 M raltegravir for 24 h. In the presence of phena-
zine methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
is converted by cellular NAD(P)H reduction in living cells into a
formazan product with a maximum absorbance at 490 to 500 nm.
PMS and MTS were therefore added to raltegravir-treated cells,
the cells were incubated for a further 2 h, and the optical density at
490 nm was then measured. As shown in Fig. 1A, up to 400 M
raltegravir did not reduce the viability of FS-2 and M210B4 cells,
while CV1 cell viability was reduced only slightly by treatment
with 100 to 200 M raltegravir. Once the concentration of ralte-
gravir was increased to 800 or 1,600 M, the viability of all three
cell lines was significantly impaired, with a 40% to 70% decline in
the absorbance at 490 nm.
To test for the effects of raltegravir on HSV replication, CV1
cells were infected with 0.01 PFU/cell HSV-1 or HSV-2 and then
treated with various concentrations of raltegravir, starting at 1 h
after infection. At 24 hpi, the cells were lysed by three cycles of
freeze-thawing, and the amount of infectious virus in CV1 cells
was determined by plaque assay. As shown in Fig. 1B, the virus
titer did not significantly decrease at drug concentrations up to 10
M, indicating that HSV-1 replication was not inhibited. At 100
M, virus infectivity was reduced 14-fold, and at 200 M the virus
titer was reduced by approximately 100-fold. HSV-2 titers (Fig.
1C) were reduced 4- to 321-fold over the range of 100 M to 400
M. On the basis of these data, the estimated effective inhibitory
concentrations required to reduce infectivity by 50% (EIC50s)
were 67.7  8.0 M and 85.8  10.0 M for HSV-1 and HSV-2,
respectively.
To determine whether raltegravir was effective against HCMV
or MCMV, FS-2 or M210B4 cells were infected with 0.01 PFU/cell
HCMV or MCMV and then treated with the same concentrations
of raltegravir 1 h after infection. At 72 hpi, the cells were lysed by
three cycles of freeze-thawing, and the amount of infectious virus
was determined by plaque assay. As shown in Fig. 1D and E, the
viral titers of HCMV were reduced 80-fold by treatment with 400
M raltegravir, whereas the viral titers of MCMV were reduced
more than 700-fold by treatment with 400 M raltegravir. The
EIC50s estimated on the basis of these data were 20.0  6.5 M
and 2.1  0.6 M for HCMV and MCMV, respectively. We con-
clude that raltegravir has antiviral activity against both alphaher-
pesviruses (HSV-1 and HSV-2) and betaherpesviruses (HCMV
and MCMV).
The next series of experiments was designed to determine the
stage of viral replication affected by raltegravir treatment. Because
we suspected that DNA cleavage might be affected, we used an
established Southern blot assay to assess this parameter (24).
Briefly, CV1 cells were infected with 5 PFU per cell of HSV-1(F).
After virus adsorption and washing, cells were maintained in me-
dium supplemented with either the DMSO carrier or 200 M
raltegravir. Uninfected cells were used as a negative control. Cells
were harvested at 18 hpi, and total cellular DNA was purified,
digested with BamHI, subjected to electrophoresis in a 0.8% aga-
rose gel, denatured, and transferred to a Zeta-Probe blotting
membrane. DNA on the membrane was then reacted with a dena-
tured 32P-labeled BamHI P fragment, which is specific for both
genomic ends and the junction between the unique long and
unique short components of the HSV-1 genome.
The results are presented in Fig. 2A. In wild-type HSV-1(F)
DNA from untreated cells, the probe recognized the S-P junction
fragment and the smaller P fragment, which is specific for the end
of the short component in linear genomes. Remarkably, raltegra-
vir did not eliminate production of the P fragment, as would be
expected if DNA cleavage were inhibited. Instead, the intensities
of both bands were reduced in the drug-treated sample compared
to those of the bands from DMSO-treated cells. Moreover, a de-
creased intensity of the BamHI viral DNA ladder in ethidium bro-
mide-stained gels was noted in raltegravir-treated samples com-
pared with that of the viral DNA ladder in DMSO-treated cells
(Fig. 2B). These data indicate that raltegravir inhibits DNA repli-
Raltegravir and DNA Polymerase Accessory Factor of HSV
October 2014 Volume 88 Number 19 jvi.asm.org 11123
 on D
ecem









FIG 1 Antiviral activities of raltegravir. (A) Cytotoxic effect of raltegravir. CV1, FS-2, and M210B4 cells at 80% confluence in 24-well plates were treated
with various concentrations of raltegravir for 24 h. After treatment, a cell proliferation reagent (Promega) was added to each well, and 2 h later, the
absorbance at 490 nm was recorded. (B and C) Specific anti-HSV-1 (B) and anti-HSV-2 (C) activity of raltegravir. Subconfluent CV1 cells in 6-well plates
were infected with HSV-1(F) or HSV-2(G) at an MOI of 0.01 PFU per cell. After 60 min of incubation at 37°C, the inocula were removed, residual
extracellular infectivity associated with the cells was reduced by treatment with a low-pH citrate buffer, and growth media containing the indicated
concentrations of raltegravir were added. At 24 h after virus infection, the amount of infectious virus was determined by plaque assay in CV1 cells. (D)
Specific anti-HCMV activity of raltegravir. Subconfluent FS-2 cells in 6-well plates were infected with HCMV at an MOI of 0.01 PFU per cell. After 60 min
of incubation at 37°C, the inocula were removed, residual extracellular infectivity associated with the cells was reduced by treatment with a low-pH citrate
buffer, and growth media containing the indicated concentrations of raltegravir were added. At 72 h after virus infection, the amount of infectious virus
was determined by plaque assay in FS-2 cells. (E) Specific anti-MCMV activity of raltegravir. Subconfluent M210B4 cells in 6-well plates were infected with
MCMV at an MOI of 0.01 PFU per cell. After 60 min of incubation at 37°C, the inocula were removed, residual extracellular infectivity associated with
the cells was reduced by treatment with a low-pH citrate buffer, and growth media containing the indicated concentrations of raltegravir were added. At
72 h after virus infection, the amount of infectious virus was determined by plaque assay in M210B4 cells. In all panels, the data represent the means and
standard errors of three replicates.
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cation directly or indirectly. Indirect mechanisms might include
lower levels of expression of DNA replication enzymes or the ini-
tiation of infection.
To confirm the inhibition of HSV-1 DNA replication by ralte-
gravir, viral DNA in infected cells was measured by qPCR. As
shown in Fig. 2C, there was an approximately 77% decrease in the
amount of UL42 target sequences in cells treated with raltegravir
compared with that in DMSO-treated samples (P  0.001). Ex-
periments were also performed with several other primer sets.
Depending on the locus analyzed, the amount of DNA in drug-
treated cells was decreased from 75 to 83% compared with that in
the DMSO-treated cells examined in parallel (data not shown).
These data indicate that raltegravir inhibits HSV DNA replication.
The absence of an apparent effect of raltegravir on DNA cleav-
age was unexpected. To determine the target of inhibition, a series
of experiments was undertaken to generate raltegravir-resistant
HSV isolates. CV1 cells infected with HSV-1 were maintained in
DMEM containing 200 M raltegravir. Fresh medium containing
the same concentration of raltegravir was added at 24-h intervals.
Progeny virus was harvested after a cytopathic effect was evident.
This virus stock was subjected to the same conditions for nine
additional cycles of infection in the presence of drug, followed by
collection of progeny virus. These progeny were then plaque pu-
rified, grown to a high titer, and tested for raltegravir resistance by
plaque assay. Of 12 isolates from this 10th passage, 2 that exhibited
the greatest resistance to raltegravir were chosen for further study
(data not shown). One of these was passaged five more times in the
presence of 200 M raltegravir and was designated clone 7. As
shown in Fig. 3A, plaque assay results show that the titer of virus
clone 7 decreased by only 3-fold in the presence of raltegravir,
while that of wild-type virus was reduced by more than 50-fold in
the presence of the drug at the same concentration.
FIG 2 Raltegravir can inhibit DNA replication of HSV-1(F). CV1 cells were infected with virus at an MOI of 5 PFU per cell. After virus adsorption and washing,
cells were maintained in medium containing DMSO alone or with 200 M raltegravir. (A) The cells were lysed, and total cellular DNA was extracted, digested
with BamHI, electrophoretically separated on 0.8% agarose gels, and transferred to nitrocellulose. (B) The gels were then probed with radiolabeled BamHI P
fragment, which is specific for sequences at genomic ends (P fragments), and internal junction fragments (S-P fragment). (C) Comparison of the DNA copies of
the viral genome of HSV-1(F) with DMSO treatment and raltegravir treatment using real-time quantitative PCR. Target primers for UL42 and reference primers
for 18S rRNA were used to quantify viral DNA. The relative amount of amplicon DNA was calculated by subtraction of the CT value of target genes and 18S rRNA
(control) gene in the raltegravir-treated samples. This difference was then substracted from the same calculation derived from the DMSO-treated samples by the
2CT method. qPCR was performed in triplicate, and data are shown as the mean  SD of three independent experiments. ***, P  0.001.
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To ensure that the resistant virus was not impaired in growth
by continuous passage in the presence of drug, CV1 cells were
infected with clone 7 or HSV-1(F) at an MOI of 0.01. At 24, 48,
and 60 hpi, the cultures were collected and virus titers were deter-
mined by plaque assay. As shown in Fig. 3B, the growth kinetics of
clone 7 were similar to those of HSV-1(F).
A series of experiments was then undertaken to identify the
mutation(s) responsible for raltegravir resistance. In the first ex-
periment, viral DNA was extracted from capsids purified from
cells infected with clone 7 and sequenced. Table 2 lists 16 muta-
tions from the published sequence of HSV-1(F) (25). The muta-
tions were distributed throughout the genome, with a single nu-
cleotide change occurring in 16 different genes. All of the reads
from these regions contained the mutations, suggesting that the
derived sequence was from a single genome containing all 16 mu-
tations. Of these mutations, 5 were silent, including a mutation in
UL29 (26), encoding the single-strand DNA-binding protein (27).
Amino acid-altering mutations were located in genes encoding
virion structural proteins and proteins required for DNA replica-
tion and packaging, such as pUL15 (encoding the large terminase
subunit) (28), pUL32 (a DNA cleavage/packaging protein) (29),
and pUL42 (DNA polymerase accessory factor) (26, 30).
Because the changes in sequence could have arisen at any time
during viral passage, including within the original virus stock, we
performed a second series of experiments to identify the target of
raltegravir. Specifically, the mutations within UL15, UL32, UL42,
and UL54 (encoding ICP27, which is an important regulatory pro-
tein) (31) were introduced into the wild type HSV-1(F) genome
using two-step red-mediated recombination, as described by
Tischer et al. (22). The recombinant viruses were designated
Mu15, Mu32, Mu42, and Mu54, respectively. CV1 cells were in-
fected with 0.01 PFU/cell of these mutant viruses or HSV-1(F) and
after adsorption were treated with DMSO carrier or 200 M ralte-
gravir. At 24 hpi, the cells were lysed by three cycles of freeze-
thawing, and the amount of infectious virus was determined by
plaque assay in CV1 cells. As shown in Fig. 4A, the viral titers of
three of the recombinant viruses (those with F198S in UL15,
A374V in UL32, and A224S in UL54) showed that they were as
susceptible to inhibition by raltegravir as HSV-1(F). In contrast,
recombinant viruses bearing the V296I mutation in UL42 (Mu42,
Mu15/42, and Mu32/42) were resistant to raltegravir, inasmuch as
the drug reduced the infectious titers by only about 4-fold, similar
to the effect of raltegravir on clone 7 replication. These data
strongly suggest that the mutation in UL42 confers resistance to
raltegravir.
To determine if the UL42 mutation restored DNA replication
to HSV-1(F) in the presence of raltegravir, cells were infected with
HSV-1(F), the clone 7 mutant, or the recombinant virus into
which the UL42 mutation was inserted (Mu42). Total DNA was
purified from the infected cells and subjected to qPCR using a pair
FIG 3 Generation of mutant virus with raltegravir-resistant activity under continuous raltegravir treatment. (A) Plaque-purified virus with high resistance was
designated clone 7 and was passaged five more times in the presence of 200 M raltegravir. Subconfluent CV1 cells in 6-well plates were infected with HSV-1(F)
or clone 7 at an MOI of 0.01 PFU per cell. After 60 min of incubation at 37°C, the inocula were removed, the residual extracellular infectivity associated with the
cells was reduced by treatment with a low-pH citrate buffer, and growth media containing 200 M raltegravir were added. At 24 hpi, the amount of infectious
virus was determined by plaque assay in CV1 cells. (B) Growth kinetics of clone 7 virus and HSV-1(F). CV1 cells were infected with clone 7 or HSV-1(F) at an
MOI of 0.01. At the indicated time points, cell cultures were collected and viral infectivity was measured by plaque assay in CV1 cells. Each point and error bar
represents the mean  SD of results from three individual experiments.








1 A9604G —a UL1 Envelope glycoprotein L
2 G11809A R182W UL4 Nuclear protein UL4
3 C12461T — UL5 Helicase-primase helicase subunit
4 T15564C — UL6 Capsid portal protein
5 C28512T V109 M UL14 Tegument protein UL14
6 T34226C F198S UL15 DNA packaging terminase
subunit 1
7 A35711G — UL18 Capsid triplex subunit 2
8 G43838A A821V UL22 Envelope glycoprotein H
9 C60590T — UL29 Single-stranded DNA-binding
protein
10 G67957A A374V UL32 DNA packaging protein UL32
11 T73069C M2434V UL36 Large tegument protein
12 T84529C C35R UL38 Capsid triplex subunit 1
13 G93893A V296I UL42 DNA polymerase accessory factor
14 T104340C T212A UL48 trans-Activating tegument protein
VP16
15 C107306A P134T UL50 Deoxyuridine triphosphatase
16 G114294T A224S UL54 Multifunctional expression
regulator
a —, no amino acid change.
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of primers specific for the UL42 gene. As expected, the Mu42- and
clone 7-infected cells both contained an increase in UL42 target
sequences compared to the levels in cells infected with HSV-1(F)
and treated with raltegravir. Additionally, there was no significant
difference in the number of copies of UL42 between clone 7- and
Mu42-infected cells (Fig. 4B). Similar observations were obtained
using primer sets specific for UL44 and UL46 (data not shown).
These data suggest that the UL42 mutation restores the replication
of HSV-1 in the presence of raltegravir.
Figure 5A shows the structure of UL42 bound to a portion of
the DNA polymerase, as previously published by Zuccola et al.
(32). Modeling of the V296I mutation into this structure (Fig. 5B)
suggests that while it is located near the polymerase-interacting
region of pUL42, the mutation is unlikely to interfere with binding
to the DNA polymerase.
DISCUSSION
A previous report showed that raltegravir can block the nuclease
activity of terminase subunit pUL89 of HCMV expressed in E. coli
(8). Given the highly conserved nature of this subunit in all her-
pesviruses and the requirement for its nuclease activity as a pre-
requisite for DNA packaging, we speculated that raltegravir would
act against a variety of herpesviruses. In this study, we show that
four herpesviruses from two subfamilies are sensitive to raltegra-
vir and the drug reduced titers up to 700-fold, depending on the
dose and the species of virus. Surprisingly, however, Southern blot
and qPCR analyses indicated that raltegravir inhibited viral DNA
replication rather than DNA cleavage (Fig. 2).
Passaging of HSV-1 in the presence of raltegravir over the
course of 4 months caused an increase in resistance to the drug. By
the 10th passage, the viral titer was reduced by 6-fold in the pres-
ence of drug (data not shown), while a further 5 passages pro-
duced a virus that replicated to titers reduced by only 3-fold (Fig.
3A). Sequencing of this highly passaged virus revealed a variety of
mutations. Of the mutations tested, the V296I mutation in UL42
increased viral resistance to raltegravir to a level similar to that of
the highly passaged virus, suggesting that UL42 was the most im-
portant target of the drug. UL42 also makes sense as the major
target because it is necessary for optimal viral DNA synthesis (33).
While a mutation (F198S) in the large terminase subunit encoded
by UL15 was noted, this mutation did not contribute additively to
drug resistance when paired with the UL42 mutation, nor did it
confer substantial resistance to raltegravir by itself. Nevertheless,
the data cannot exclude the possibility that one or more of the
mutations other than UL42 V296I contribute to raltegravir resis-
tance.
Structural modeling suggests that UL42 V296I is unlikely to
interfere with the critical binding of the UL42 gene product to the
HSV DNA polymerase (Fig. 5). This prediction is supported by
the observation that the cadres of mutations, including UL42
V296I, did not impair viral growth in the absence of raltegravir
(Fig. 3B). We hypothesize that the UL42 V296I mutation blocks
drug binding to UL42 or to other components of the DNA repli-
cation complex which comprises UL42, the polymerase, and heli-
case and primase components.
The drug resistance of viruses is an important consideration
for antiviral therapy. While raltegravir might be effective against
HIV and herpesviruses, drug resistance arises due to the emer-
FIG 4 A single amino acid mutation in UL42 confers raltegravir resistance. (A)
Identification of the virus titers of the recombinant viruses corresponds to
different amino acid mutations. Subconfluent CV1 cells in 6-well plates were
infected with recombinant viruses as well as HSV-1(F) at an MOI of 0.01 PFU
per cell. After 60 min of incubation at 37°C, the inocula were removed, residual
extracellular infectivity associated with the cells was reduced by treatment with
a low-pH citrate buffer, and growth media containing 200 M raltegravir were
added. At 24 hpi, the amount of infectious virus was determined by plaque
assay in CV1 cells. (B) Comparison of the viral DNA copies of HSV-1(F), clone
7, and Mu42 with DMSO treatment or raltegravir treatment using real-time
qPCR. CV1 cells were infected with these three viruses at an MOI of 5 PFU per
cell. After virus adsorption and washing, cells were maintained in medium
containing 200 M raltegravir or an equivalent of DMSO carrier. The cells
were lysed, and total cellular DNA was extracted and used as the template for
qPCR, as described previously (see Fig. 2C). qPCR was performed in triplicate,
and data are shown as the mean  SD of three independent experiments. ns,
not significant (P  0.05); **, P  0.01; ***, P  0.001.
FIG 5 (A) pUL42 residue V296 (red) is located next to the interface of pUL42
(molecular surface in blue) and the bound C-terminal tail of the viral DNA
polymerase catalytic subunit (ribbon diagram in green) (RCSB PDB accession
code 1DML) (32). (B) V296 is mutated to Ile (stick model in red) in pUL42
(ribbon diagram in blue), showing no steric clash with binding of the DNA
polymerase C-terminal tail (molecular surface in green). The two panels are in
the same view.
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gence of HIV variants (34, 35) that contain amino acid changes in
the integrase. These are especially important in severely immuno-
compromised patients receiving prolonged antiviral therapy, such
as transplant recipients and AIDS patients. The currently ap-
proved antiherpesvirus agents acyclovir (ACV), penciclovir
(PCV), ganciclovir (GCV), cidofovir (CDV), and foscarnet (PFA)
ultimately target the viral DNA polymerase. Molecular mecha-
nisms of HSV resistance to ACV most often involve mutations
within genes encoding either the viral thymidine kinase (UL23) or
the DNA polymerase (UL30) (36, 37). In transplant recipients, the
drug resistance of human cytomegalovirus is caused by mutations
in either the viral kinase encoded by UL97 or the gene encoding
viral DNA polymerase (UL54) (38). Following the development of
genotypic testing (39, 40) and BAC technology (41), novel muta-
tions in genes involved in viral DNA replication have been shown
to confer drug resistance. Our finding that a mutation in HSV-1
UL42 can confer resistance to raltegravir therefore adds another
mutation to a growing list. We also caution that raltegravir targets
in HSV-2, MCMV, and HCMV may or may not map to the cor-
responding DNA polymerase accessory factors of these viruses;
certainly, this possibility warrants further investigation.
Our results demonstrate that raltegravir treatment might com-
prise part of an effective strategy to control HSV and HIV coin-
fection. While the long-term use of raltegravir alone may cause the
emergence of drug-resistant HIV and herpesviruses, its use as part
of a combination therapy against these pathogens warrants eval-
uation.
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